The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -9,552 | -7,786 | -5,891 | -11,863 |
| Allowance for credit losses (recoveries) | -95 | -196 | 0 | 217 |
| Depreciation and amortization | 86 | 249 | 66 | 499 |
| Amortization of intangible assets | 504 | 168 | - | - |
| Share-based compensation | 2,218 | 1,981 | 2,022 | 4,177 |
| Payment-in-kind interest | 525 | 418 | 318 | 172 |
| Amortization of debt issuance costs and original issue discounts | 42 | 23 | 39 | 21 |
| Amortization of lease right of use assets, net of accretion in lease liabilities | 523 | 434 | 360 | 461 |
| Accounts receivable | 2,019 | 765 | -260 | -237 |
| Inventory, net | 125 | 87 | 498 | -482 |
| Prepaid expenses and other current assets | -653 | -299 | 560 | 136 |
| Other assets | 71 | 3 | 192 | 0 |
| Accounts payable and accrued expenses | -437 | -6,269 | 693 | -1,944 |
| Lease liabilities | -391 | -296 | -245 | -471 |
| Contract liabilities | 172 | -250 | 507 | -576 |
| Net cash flows from operating activities | -7,967 | -12,080 | -3,121 | -8,724 |
| Cash acquired in business combination, net of cash paid | - | 1,137 | - | - |
| Purchases of property and equipment | 645 | 49 | 199 | 274 |
| Proceeds from issuance of common stock under employee stock purchase plan | - | 248 | 0 | 311 |
| Net cash flows from investing activities | -645 | 1,088 | -199 | -274 |
| Proceeds from offerings of common stock, net of offering costs | - | 0 | 0 | 3,263 |
| Proceeds from issuance of notes payable, net of financing costs and discount | - | 19,433 | 0 | 28,653 |
| Repayment of 2020 senior secured convertible note | - | 0 | 0 | - |
| Payment of at-the-market offering costs | 0 | - | - | - |
| Proceeds from stock option exercises | 148 | 78 | 0 | 49 |
| Payments for taxes related to net share settlement of equity awards | 1,993 | 195 | 0 | 1,661 |
| Net cash flows from financing activities | -1,845 | 19,564 | 0 | 30,615 |
| Net change in cash, cash equivalents and restricted cash | -10,457 | 8,572 | -3,320 | 21,617 |
| Cash, cash equivalents and restricted cash, beginning of period | 46,973 | 38,401 | 20,104 | - |
| Cash, cash equivalents and restricted cash, end of period | 36,516 | 46,973 | 38,401 | - |
ClearPoint Neuro, Inc. (CLPT)
ClearPoint Neuro, Inc. (CLPT)